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maximization method was used to identify a SIP cut-off level and dichotomize pts
accordingly. The objective was to correlate SIP with clinical characteristics and RECIST
response by univariate logistic regression analysis.
Results: 37 aNSCLC pts were evaluable for SIP before IO: 32% 65 years, 91% non-
squamous, 43%KRASmutated, 51%with PD-L1 expression1%, 8% chemotherapy
naı¨ve. 43% had PD, 41% stability (SD), 16% partial response (PR). Median PFS and OS
were 2.7 (95%CI 1.8; 7.3) and 13 (95%CI 4.8-NR)months, respectively, median
follow-up was 9.3 (95% CI 6.2-14.9) months. SIP (%CD28-CD57þKLRG1þ) median
value on circulating CD8þ lymphocytes was 12.2% (min 1.7%, max 56.1%). 32% of pts
had>20.47%CD8þ lymphocytes with a CD28-CD57þKLRG1þ phenotype, being clas-
sified SIPþ. SIP status did not significantly correlate with age, pts’ characteristics or
CT exposure. 2 (17%) of 12 SIPþ had PR/SD (DCR), vs 19 (76%) of 25 SIP- pts
(p¼ 0.001); median PFS was significantly lower in SIPþ (1.5 months 95%CI 1;2.2) vs
SIP- pts (7.4 months 95%CI 5.5, 9.3) (p¼ 0.001). Among 61 aNSCLC pts treated with
1st line PCT, 18% had PD, 43% SD, 39% PR. SIP median value on circulating CD8þ
lymphocytes was 17.9% (min 0.89%,max 66.1%), 43% of pts were SIPþ. SIP did not
significantly correlate with DCR (OR: 0.82, 95% CI 0.22-3.13, p¼ 0.82) upon PCT.
Conclusions: iSenescence, monitored by FCmeasurement of 3 surface molecules on
circulating CD8 þ lymphocytes, is observed in 32% and 43% of aNSCLC pts before IO
or PCT, respectively. SIP correlated with lower DCR upon IO and not PCT.
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Background: The tumor mutation burden (TMB) is emerging as a prognostic and pre-
dictive marker for the response to immune checkpoint blockade (ICB) drugs. We
aimed to develop a newmethod for the definition of gene panels that can precisely esti-
mate the TMB with a considerably lower amount of genome.
Methods:We developed a bioinformatic pipeline which allows the design of gene pan-
els suited for TMB estimation. The method is particularly efficient in optimizing the
balance between the precision of the TMB estimate and the length of the gene panel cre-
ated. We tested in silico the efficiency of different panels obtained with ourmethod in
an independent cohort of patients with lung adenocarcinoma (LUAD).We also com-
pared in the same cohort of patients the performance of our panels with the perform-
ance of existing gene panels.
Results:We designed a 0.080Megabases (Mb) long gene panel which estimated TMB
in an independent LUAD cohort with an acceptable precision (adjusted R2¼0.745;
Spearman q¼ 0.827, Pearson q¼ 0.864). The panel showed 0.89 accuracy in the identi-
fication of TMB-high patients (25/28 patients, CI: 0.73 – 0.96). Every unitary increase
of our TMB estimate was associated with lower risk of disease progression (univariate
analysis: HR¼ 0.78; CI: 0.65-0.93; p¼ 0.006; multivariate analysis: HR¼ 0.8; CI: 0.63-
1.01; p¼ 0.0621). Different existing panels of less than 1Mb long showed a lower
adjusted R2 when compared to our gene panel (Table). Two other commercial panels
of 1.9Mb and 1.1Mb showed a similar adjusted R2 to panels of the same lengths built
with our method; nevertheless, they showed a lower accuracy in TMB-high patients
definition (ROC curves AUC of 0.862, 0.870, 0.946 and 0.967 were observed, respec-
tively, for the commercial 1.9Mb panel, the commercial 1.1Mb panel, our 0.080Mb
panel and our 2.0Mb panel).
Conclusions:Ourmethod allows the design of gene panels particularly suitable for the
TMB estimation in patients with LUAD and outperforms existing gene panels less than
1Mb long.
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Background: Treatment resistance andmetastasis are linked to cancer stem cells
(CSCs). This population represents a promising target, but remains unexplored in lung
cancer. Themain objective of this study was to characterize lung CSCs and discover
new therapeutic strategies.
Methods: The study was performed on NSCLC cells from 8 resected patients and 12
cell lines. Suspension cultures (tumorspheres) were established for CSCs enrichment
and differentiated tumor cells were cultured as monolayers (2D). The CSCs properties
of tumorspheres were assessed in vitro and in vivo. The expression of 60 CSC-related
genes was analyzed by RTqPCR and the expression of 12 proteins was evaluated by
immunoblot (IB) and immunofluorescence (IF). High-throughput screening was per-
formed using Prestwick andMyria libraries. Selected drugs were administered intraper-
itoneally to NOD/SCIDmice with tumors induced by NSCLC patient and H1650
tumorspheres.
Results: Lung tumorspheres showed unlimited exponential growth (>30 passages),
great tumor initiation potential, differentiation capacity, and high resistance to chemo-
therapy agents, but not to salinomycin. Tumorspheres had significantly higher expres-
sion of CSC-related genes (ALDH1A1, KLF4, NANOG, CD44, CD90, CDKN1A,
JUNB,MDM2), invasion promoters (MMP9, SNAI1, ITGA6), and Notch (NOTCH1,
NOTCH3, DLL4, JAG1) andWnt (CTNNB1, GSK3B) components than their paired
adherent-cultured cells. IB confirmed the overexpression of proteins encoded by CD44,
NANOG, CDKN1A, SNAI1, ITGA6, and NOTCH3, and IF showed different localiza-
tion patterns on lung adenocarcinoma tumorspheres compared with the 2D cultures.
Three novel drugs [Disulfiram (DSF), Compound 1 (COMP1) and Compound 2
(COMP2)] with greater cytotoxic potential against lung tumorspheres thanmonolayer
cells were identified. These results were validated in vivo, demonstrating the capacity of
these drugs to reduce tumor growth in mice.
Conclusions: Tumorspheres are a useful culture platform for CSCs characterization in
a simple and cost-effective way.We found three drugs which are able to diminish the
formation and viability of tumorspheres, constituting promising therapies against lung
CSCs. Supported by CB16/12/00350, PI12-02838, and PI15-00753 from ISCIII.
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Table: 24P
Performance (adjusted R2) in TMB estimation of existing gene panels






panel #1 (0.187Mb) 0.76 0.83 (0.187Mb)
panel #2 (0.240Mb) 0.58 0.85 (0.25Mb)
panel #3 (0.300Mb) 0.69 0.85 (0.25Mb)
panel #4 (0.98Mb) 0.81 0.91 (0.98Mb)
panel #5 (1.1Mb) 0.92 0.92 (1.1Mb)
panel #6 (1.9Mb) 0.93 0.93 (2.0Mb)
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